Hodgkin Lymphoma News
- Patient With Blood Cancer Takes on Bias and 'Gaslighting'
- ESMO Breast Cancer 2023 Patritumab Deruxtecan Shows Promise for Breast Cancer
- ESMO Breast Cancer 2023 T-DXd for HER2-Low BC: Analysis Confirms Adverse Effects
- Repeated CTs in Childhood Linked With Increased Cancer Risk
- Healthy Lifestyle Mitigates Impact of Childhood Cancer
- Pfizer in Talks to Buy Cancer Drugmaker Seagen
- Could Your Patients Benefit? New Trials in Lung Cancer
- New Trials in Urologic Cancers: Could Your Patient Benefit?
- Loneliness Risk Elevated Among Young Cancer Survivors
- Cardioprotection for 20 Years for Children With Cancer
- Novel HER2 Assay to Predict HER2+ Breast Cancer Tx Response
- Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer Tx
- New Trials in Leukemia and Lymphoma: Could Your Patient Benefit?
- SABCS 2022 HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact?
- SABCS 2022 T-DXd: 'Remarkable' Survival Gains in Advanced Breast Cancer
- ASH 2022 Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging
- SABCS 2022 High Response Rates With T-DXd in Early HER2-Low Breast Cancer
- ASH 2022 ASH 2022: New Clinical Data Challenge Long-held Assumptions
- Alert Blenrep for Multiple Myeloma Withdrawn From US Market
- Brentuximab in Pediatric HL: 'Paradigm Shift' and Just Approved